Potent and Targeted Sindbis Virus Platform for Immunotherapy of Ovarian Cancer.

Autor: Opp S; Department of Pathology, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA., Hurtado A; Department of Pathology, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA., Pampeno C; Department of Pathology, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA., Lin Z; Department of Pathology, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA., Meruelo D; Department of Pathology, NYU Grossman School of Medicine, New York University, New York, NY 10016, USA.
Jazyk: angličtina
Zdroj: Cells [Cells] 2022 Dec 24; Vol. 12 (1). Date of Electronic Publication: 2022 Dec 24.
DOI: 10.3390/cells12010077
Abstrakt: Our laboratory has been developing a Sindbis viral (SV) vector platform for treatments of ovarian and other types of cancers. In this study we show that SV.IL-12 combined with an agonistic OX40 antibody can eliminate ovarian cancer in a Mouse Ovarian Surface Epithelial Cell Line (MOSEC) model and further prevent tumors in mice rechallenged with tumor cells after approximately 5 months. Treatment efficacy is shown to be dependent upon T-cells that are transcriptionally and metabolically reprogramed. An influx of immune cells to the tumor microenvironment occurs. Combination of sequences encoding both IL-12 and anti-OX40 into a single SV vector, SV.IgGOX40.IL-12, facilitates the local delivery of immunoregulatory agents to tumors enhancing the anti-tumor response. We promote SV.IgGOX40.IL-12 as a safe and effective therapy for multiple types of cancer.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje